For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  Survodutide
Weight & Metabolicphase_2_3

Survodutide

BI 456906
Weight & Metabolic · CAS 2152821-25-5
ASK VERA ABOUT THIS ↗BUY NOW ↗
Category
Weight & Metabolic
Evidence grade
B
PubMed records
71
Female-tagged
10
Sex-analysis
1
CAS
2152821-25-5
B
Evidence grade B, Phase 2/3 human trial evidence across 71 indexed studies (mixed-sex). How grades work →
Female evidence: Extrapolated
Survodutide: of 71 PubMed records, 10 are tagged as including female subjects and 1 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

Survodutide (BI 456906) is a synthetic, lipidated long-chain peptide that acts as a dual agonist of the GLP-1 and glucagon receptors, used as a tool compound in metabolic and incretin research. Its dual-receptor design places it among the multi-agonist compounds developed after single-target GLP-1 agents.

In vitro and in preclinical systems, survodutide has been studied for its combined receptor pharmacology and its modeled effects on energy-expenditure, glucose-handling, and hepatic lipid-metabolism pathways. Investigators examining incretin and glucagon biology have used it as a research material to probe how simultaneous engagement of two receptors influences metabolic signaling.

Supplied for in-vitro and laboratory research only, survodutide is a useful weight and metabolic catalog entry because it isolates a defined dual-agonist mechanism. Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.

Summary

Survodutide (BI 456906) is a GLP-1/glucagon dual-receptor agonist in Phase 2/3 development for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Trials have enrolled women, but published results are not analyzed by sex.

Evidence in women

Menstrual cycle
Unstudied
No study examined metabolic response across the menstrual cycle.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data; incretin agonists are generally avoided in pregnancy.
Hormonal interactions
Unstudied
Possible effects on oral contraceptive absorption via gastric emptying have not been studied for survodutide.
Perimenopause & menopause
Unstudied
No perimenopause- or menopause-specific analyses.
Sex differences
Unstudied
Women were enrolled, but outcomes were not analyzed by sex.

Mechanism

A dual agonist that co-activates GLP-1 and glucagon receptors to reduce appetite and improve hepatic and metabolic endpoints.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Doses up to ~6 mg subcutaneous weekly in Phase 2 trials; investigational.
Routessubcutaneous
Female-specific dosingNot established

Contraindications: personal or family history of medullary thyroid carcinoma or MEN2 (incretin class effect, theoretical)

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

nauseavomitingdiarrhea

Survodutide reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for Survodutide

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from Survodutide's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is Survodutide?

Survodutide, also known as BI 456906, is a research compound in our weight metabolic category. Survodutide (BI 456906) is a GLP-1/glucagon dual-receptor agonist in Phase 2/3 development for obesity and metabolic dysfunction-associated steatohepatitis (MASH).

Is Survodutide studied in women?

Survodutide: of 71 PubMed records, 10 are tagged as including female subjects and 1 carry a sex-analysis tag. We grade this extrapolated: women appear in the record, but no study is tagged for a sex-specific analysis, so female-relevant conclusions are inferred from mixed or male data rather than measured in women. See our methodology.

Has Survodutide been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data; incretin agonists are generally avoided in pregnancy. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does Survodutide have, and why?

Survodutide carries evidence grade B. Phase 2/3 human trial evidence across 71 indexed studies (mixed-sex).. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for Survodutide?

No. A female-specific dose for Survodutide is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is Survodutide administered in research?

In the published literature, Survodutide is administered via subcutaneous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for Survodutide?

Effects reported in the research literature include nausea, vomiting, diarrhea. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

What is the CAS number for Survodutide?

The CAS registry number for Survodutide is 2152821-25-5. It is also referred to as BI 456906. Use it to confirm identity against a Certificate of Analysis.

How should Survodutide be stored and handled?

Survodutide sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy Survodutide for research?

For laboratory research use, Survodutide is available from our research-use partner, Aurevena Research. Applying code research15 takes 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Buy Survodutide at Aurevena Research
Research-use supplier: Survodutide is available from our research-use vendor for laboratory use. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Buy now →

Citations (PMID)

38843460 · 40590228

Related peptides

4X Blend (Methionine / Choline / Carnitine / Dexpanthenol)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
5-Amino-1MQD
5-Amino-1MQ: of 3 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.
8X Blend (L-Carnitine / L-Arginine / Methionine / Inositol / Choline / B6 / B5 / B12)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
AdipotideD
Adipotide: of 4 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.